Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

Learning Objectives Evaluate the mechanism of action of vandetanib in the care of patients with thyroid cancer. Analyze the current status of clinical development and early clinical results observed with vandetanib. Determine appropriate dose and schedule of administration, safety, and identification of molecular biomarkers predictive of response. This article is available for continuing medical education credit at CME.TheOncologist.com.